// App-Quantinova.ai

5027 : Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Anis Hamid

Principal Investigators

  • Mathias Bressel

  • Louise Emmett

  • Anthony M. Joshua

  • Lavinia Anne Spain

  • Lisa Horvath

  • Megan Crumbaker

  • Anupama Pasam

  • Jason Callahan

  • Alisa Tubbs

  • Luisa Fernandez

  • Richard J. Wenstrup

  • Grace Kong

  • Jeremy Howard Lewin

  • Ben Tran

  • Arun Azad

  • Joseph D. Schonhoft

  • Rodney J. Hicks

  • Shahneen Sandhu

Medical Centers

  • Eastern Health and University of Melbourne, Melbourne, Australia

  • Division of Cancer Medicine, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia

  • Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Australia

  • Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, Australia

  • The Kinghorn Cancer Centre, St Vincents Hospital, Sydney, Australia

  • Epworth Healthcare and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

  • Chris O'Brien Lifehouse, Sydney, Australia

  • St Vincents Hospital, Sydney, Australia

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Epic Sciences, Inc., San Diego, CA

  • Division of Cancer Medicine, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • St. Vincent’s Medical School, University of Melbourne, Melbourne, Australia

Locations

  • Australia

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Urology

  • Oncology (ONC)

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

  • Protein Tyrosine Phosphatase, Receptor Type C

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT03658447

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved